awmsg logo



bortezomib (Velcade®)


Reference No. 1807

Publication date:
31/10/2014


Appraisal information

bortezomib (Velcade®) 3.5 mg powder for solution for injection


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 10/09/2014
AWMSG meeting date: 08/10/2014
   
   
Submission Type: Limited Submission
Status: Recommended with restrictions
Advice No: 2814
Ministerial ratification: 30/10/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Bortezomib (Velcade®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. Bortezomib (Velcade®) should be restricted for use in combination with dexamethasone. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised. Bortezomib (Velcade®) is not recommended for use within NHS Wales in combination with pegylated liposomal doxorubicin.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download